Twist Bioscience CFO Robert Werner sells 853 shares at $27.69 on August 25, 2023.

Twist Bioscience Corp. has announced that Chief Accounting Officer Werner Robert F. has sold 853 shares of the company at a price of $27.69 per share on August 25, 2025.

Twist Bioscience Corp. (TWST) has announced that Chief Accounting Officer Werner Robert F. sold 853 shares of the company's Common Stock on August 25, 2025, at a price of $27.691 per share, totaling $23,620. This sale was to cover tax withholding obligations related to the vesting of Restricted Stock Units [1].

Following this transaction, Werner directly owns 48,689 shares of Twist Bioscience Corp. The sale is significant as it indicates a shift in the company's financial landscape, potentially signaling a move to meet its tax obligations. However, it is essential to note that this transaction does not necessarily reflect the company's overall financial health or its stock valuation.

In the broader context, Twist Bioscience has been experiencing a challenging year for its stock, with shares down 35% over the past year despite ongoing operational progress. The company's annual revenue is growing at 15%, and net income losses are narrowing, suggesting a cautious yet improving financial situation. The recent product launch of the customizable Oncology DNA Comprehensive Genomic Profiling (CGP) Panel further underscores the company's focus on innovation in genomics and oncology research [2].

The market's skepticism towards Twist Bioscience's stock has led some analysts to suggest that the stock may be undervalued. According to Simply Wall St, the fair value estimate for Twist Bioscience is $40.00, indicating a potential buying opportunity. However, the company's reliance on a few key customers and persistent losses could pose risks to its future profitability [2].

In conclusion, the sale of shares by Chief Accounting Officer Werner Robert F. is a notable event for Twist Bioscience Corp. While it provides insight into the company's tax obligations, it does not necessarily reflect its overall financial health or stock valuation. Investors should consider the broader context, including the company's recent product launch and analysts' valuation estimates, when making investment decisions.

References:
[1] https://www.tradingview.com/news/tradingview:9d510297e9f7f:0-twist-bioscience-corp-officer-sells-shares-to-cover-tax-obligations/
[2] https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-twst/twist-bioscience/news/twist-bioscience-twst-examining-valuation-after-launch-of-cu